Table 2.

Multivariate analysis of OS of the 510 patients

		Patients n = (%)	HR (95% CI)	P value
Total number		510 (100)
Group	Simple chemotherapy	255 (50.0)	0.175 (0.140–0.219)	<0.001
	Gefitinib	255 (50.0)
Age (year)	<60	328 (64.3)	0.787 (0.649–0.955)	0.015
	≥60	182 (35.7)
Gender	Male	210 (41.2)	1.243 (0.993–1.555)	0.058
	Female	300 (58.8)
Smoking history	No	394 (77.3)	2.103 (1.608–2.750)	<0.001
	Yes	116 (22.7)
ECOG PS	0–1	481 (94.3)	1.119 (0.761–1.645)	0.568
	≥2	29 (5.7)
Stage	IIIB	37 (7.3)	0.871 (0.589–1.290)	0.491
	IV	473 (92.7)
Organ metastasis	No	277 (54.3)	0.934 (0.773–1.130)	0.483
	Yes	233 (45.7)
Pleural	No	280 (54.9)	1.115 (0.913–1.361)	0.286
	Yes	230 (45.1)
Bone	No	333 (65.3)	1.100 (0.901–1.343)	0.351
	Yes	177 (34.7)
Brain	No	384 (75.3)	1.099 (0.883–1.368)	0.399
	Yes	126 (24.7)
Adrenal gland	No	487 (95.5)	1.193 (0.765–1.861)	0.436
	Yes	23 (4.5)
Liver	No	466 (91.4)	1.501 (1.085–2.077)	0.014
	Yes	44 (8.6)
Prior chemo	1–2	414 (81.2)	0.298 (0.230–0.386)	<0.001
	≥3	96 (18.8)

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PS, performance status.